181 episodes

News and views from the world of clinical oncology and hematology.

The ASCO Post Podcast BroadcastMed

    • Health & Fitness

News and views from the world of clinical oncology and hematology.

    IASLC WCLC 2020: Research in Mesothelioma, Small Cell Lung Cancer, and Drug Development

    IASLC WCLC 2020: Research in Mesothelioma, Small Cell Lung Cancer, and Drug Development

    This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development.
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re again focusing on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic. We’ll hear about findings in mesothelioma, small cell lung cancer, and drug development. 

    • 14 min
    IASLC WCLC 2020: Updates From the ADAURA Trial and More

    IASLC WCLC 2020: Updates From the ADAURA Trial and More

    This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re hearing from two thoracic oncologists on research presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer Singapore, which was moved to a virtual format and held January 28 to 31, 2021, in light of the COVID-19 pandemic.

    • 16 min
    Prevalence of KRAS G12C Mutations Across Different Populations

    Prevalence of KRAS G12C Mutations Across Different Populations

    This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
    Coverage of stories discussed this week on ascopost.com:
    Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
    FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
    This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
    Coverage of stories discussed this week on ascopost.com:
    Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
    FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:
    This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
    Coverage of stories discussed this week on ascopost.com:
    Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
    FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
    This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
    Coverage of stories discussed this week on ascopost.com:
    Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
    FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Previously Treated Patients With HER2-Positive Gastric Cancers
    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive ALCL
    This week, we’ll discuss the findings of a study that examined the prevalence of KRAS G12C mutations across different populations. Then, we’ll hear recent news about FDA oncology drug approvals in the month of January.
    Coverage of stories discussed this week on ascopost.com:
    Prevalence of KRAS G12C Somatic Mutations by Cancer Type, Race, and Sex
    FDA Approves Crizotinib for Children and Young Adults With Re

    • 13 min
    More From GI21: Findings in Gastric Cancer, Cholangiocarcinoma, and Pancreatic Cancer

    More From GI21: Findings in Gastric Cancer, Cholangiocarcinoma, and Pancreatic Cancer

    This week, we’re back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1-mutated cholangiocarcinoma, and the POLO trial in BRCA-mutated pancreatic cancer.
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’re back for more coverage of the 2021 Gastrointestinal Cancers Symposium, hearing about the FIGHT trial in advanced gastric/gastroesophageal junction adenocarcinoma, the ClarIDHy study in IDH1-mutated cholangiocarcinoma, and the POLO trial in BRCA-mutated pancreatic cancer.

    • 15 min
    Findings From the 2021 Gastrointestinal Cancers Symposium

    Findings From the 2021 Gastrointestinal Cancers Symposium

    The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We’re discussing findings from the meeting with three study authors.
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> The 2021 Gastrointestinal Cancers Symposium, held in a virtual format this year, is being held this weekend, January 15th to 17th, 2021. We’re discussing findings from the meeting with three study authors.

    • 13 min
    IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Patients With Advanced Colon Cancer

    IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Patients With Advanced Colon Cancer

    This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
    Coverage of stories discussed this week on ascopost.com:
    Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
    Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
    This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
    Coverage of stories discussed this week on ascopost.com:
    Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
    Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Coverage of stories discussed this week on ascopost.com:
    This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
    Coverage of stories discussed this week on ascopost.com:
    Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
    Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
    This week, we’ll review a meta-analysis of several trials studying the efficacy of 3 vs 6 months of adjuvant chemotherapy for patients with advanced colon cancer. We’ll also discuss a report on the frequency of osteonecrosis of the jaw among patients with metastatic bone disease treated with zoledronic acid, as well as several risk factors for the development of the condition.
    Coverage of stories discussed this week on ascopost.com:
    Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
    Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
    To listen to more podcasts from ASCO, visit asco.org/podcasts.
    "}" data-sheets-userformat= "{"2":769,"3":{"1":1},"11":4,"12":0}"> Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease

    • 12 min

Top Podcasts In Health & Fitness

The Imperfects
Hugh van Cuylenburg, Ryan Shelton & Josh van Cuylenburg
Huberman Lab
Scicomm Media
But Are You Happy?
Mamamia Podcasts
On Purpose with Jay Shetty
iHeartPodcasts
ZOE Science & Nutrition
ZOE
Ladies, We Need To Talk
ABC listen

You Might Also Like